Bioagilytix Labs
BioAgilytix Labs, a leading global bioanalytical laboratory, is headquartered in the United States and operates across major regions including Europe and Asia. Founded in 2008, the company has established itself in the biopharmaceutical industry, specialising in high-quality bioanalytical services that support drug development and regulatory submissions. With a focus on large molecule bioanalysis, BioAgilytix offers unique capabilities in pharmacokinetics, immunogenicity, and biomarker analysis. Their state-of-the-art technology and experienced team enable them to deliver precise and reliable results, setting them apart in a competitive market. Recognised for their commitment to quality and innovation, BioAgilytix Labs has achieved significant milestones, solidifying their position as a trusted partner for biopharmaceutical companies worldwide.
DitchCarbon Score
How does Bioagilytix Labs's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Bioagilytix Labs's score of 27 is higher than 51% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Bioagilytix Labs's reported carbon emissions
BioAgilytix Labs, headquartered in the United States, has made significant commitments towards achieving net-zero carbon emissions. As of the latest available data, the company has not reported any specific carbon emissions figures in kg CO2e. However, BioAgilytix has committed to long-term net-zero targets, aiming for a comprehensive reduction across all scopes of emissions by 2050. This commitment was formalised in 2023, with the company actively participating in the Science Based Targets initiative (SBTi). The company’s net-zero commitment reflects its dedication to addressing climate change within the pharmaceuticals, biotechnology, and life sciences sector. Although specific reduction targets have not been disclosed, the commitment to net-zero emissions indicates a proactive approach to sustainability and environmental responsibility. BioAgilytix Labs is focused on integrating climate action into its operational strategies, aligning with industry standards and expectations for corporate climate responsibility.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Bioagilytix Labs is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
